Circulating leptin and adiponectin levels in patients with primary hyperparathyroidism

Area of Science:

• Endocrinology
• Cardiovascular Medicine
• Metabolic Disorders

Background:

• Primary hyperparathyroidism (PHPT) is associated with increased cardiovascular morbidity and mortality.
• The exact pathogenesis of PHPT and its link to metabolic abnormalities remain unclear.
• Adipocyte-secreted substances like leptin and adiponectin influence energy homeostasis and cardiovascular health.

Purpose of the Study:

• To investigate the relationship between serum leptin and adiponectin levels and metabolic disorders in patients with newly diagnosed, treatment-naive PHPT.
• To compare these levels with those in healthy subjects.
• To explore potential pathogenetic roles in cardiovascular disease.

Main Methods:

• Studied 67 newly diagnosed, never-treated PHPT patients and 46 healthy subjects (HS).
• Assessed serum leptin and adiponectin levels.
• Evaluated metabolic syndrome using Adult Treatment Panel III criteria and correlated hormone levels with anthropometric and metabolic parameters.

Main Results:

• Twenty-nine-point-eight percent of PHPT patients had metabolic syndrome.
• PHPT patients exhibited significantly higher leptin levels compared to HS (34.28 vs. 6.28 ng/mL).
• PHPT patients with metabolic syndrome showed elevated leptin (52.63 ng/mL) and reduced adiponectin (4.34 mug/mL) levels, with significant correlations to BMI, waist circumference, cholesterol, and fasting glucose.

Conclusions:

• Increased serum leptin and decreased serum adiponectin levels are present in PHPT patients, particularly those with metabolic syndrome.
• These altered adipokine levels may contribute to the metabolic abnormalities and cardiovascular disease risk associated with PHPT.
• Further research is warranted to elucidate the precise mechanisms involved.